AMR local indicators - produced by the UKHSA

About the AMR local indicators

Data have been uploaded across six domains: The AMR local indicators are produced by the UKHSA.

  • Supporting NHS England Initiatives
  • Antimicrobial Resistance (AMR)
  • Antibiotic Prescribing
  • Healthcare-Associated Infections (HCAI)
  • Infection Prevention and Control (IPC)
  • Antimicrobial stewardship (AMS)

Antibiotic prescribing and antibiotic resistance are inextricably linked, as overuse and incorrect use of antibiotics are major drivers of resistance. AMR local indicators are publically available data intended to raise awareness of antibiotic prescribing, AMR, HCAI, IPC and AMS; and to facilitate the development of local action plans. The data published in this tool may be used by healthcare staff, commissioners, directors of public health, academics and the public to compare the situation in their local area to the national picture.

For further information about this profile, please click here to download the user guide.

Updated indicators

October 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Healthcare Associated Infections Area: Acute Trusts, Sub ICBs up to August 2024

Area – ICB sub-locations

1. C. difficile infection 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month

2. C. difficile infection 12-month rolling case counts and rates of community onset-community associated, by Sub ICB Location (SICBL) and month

3. C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by Sub ICB Location (SICBL) and month

4. C. difficile infection case counts and rates, by Sub ICB Location (SICBL) and financial year

5. C. difficile infection case counts and rates of community onset-healthcare associated, by Sub ICB Location (SICBL) and financial year

6. C. difficile infection case counts and rates of community onset-community associated, by Sub ICB Location (SICBL) and financial year

7. E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month

8. E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month

9. E. coli bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month

10. E. coli bacteraemia case counts and rates, by Sub ICB Location (SICBL) and financial year

11. E. coli bacteraemia case counts and rates of community-onset, by Sub ICB Location (SICBL) and financial year

12. Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month

13. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month

14. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month

15. Klebsiella spp. bacteraemia case counts and rates of community-onset, by Sub ICB Location (SICBL) and financial year

16. Klebsiella spp. bacteraemia case counts and rates, by Sub ICB Location (SICBL) and financial year

17. MRSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month

18. MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month

19. MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month

20. MRSA bacteraemia case counts and rates, by Sub ICB Location (SICBL) and financial year

21. MRSA bacteraemia case counts and rates of community-onset, by Sub ICB Location (SICBL) and financial year

22. MSSA bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month

23. MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month

24. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month

25. MSSA bacteraemia case counts and rates, by Sub ICB Location (SICBL) and financial year

26. MSSA bacteraemia case counts and rates of community-onset, by Sub ICB Location (SICBL) and financial year

27. P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by Sub ICB Location (SICBL) and month

28. P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by Sub ICB Location (SICBL) and month

29. P. aeruginosa bacteraemia 12-month rolling case counts and rates, by Sub ICB Location (SICBL) and month

30. P. aeruginosa bacteraemia case counts and rates of community-onset, by Sub ICB Location (SICBL) and financial year

31. P. aeruginosa bacteraemia case counts and rates, by Sub ICB Location (SICBL) and financial year

"Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.”

Area – Acute Trusts

1. C. difficile infection 12-month rolling case counts and rates, by reporting acute trust and month

2. C. difficile infection 12-month rolling case counts and rates of community onset-healthcare associated, by reporting acute trust and month

3. C. difficile infection 12-month rolling case counts and rates of hospital onset-healthcare associated cases, by reporting acute trust and month

4. C. difficile infection case counts and rates, by reporting acute trust and financial year

5. C. difficile infection case counts and rates of hospital onset-healthcare associated, by reporting acute trust and financial year

6. C. difficile infection case counts and rates of community onset-healthcare associated, by reporting acute trust and financial year

7. E. coli bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month

8. E. coli bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month

9. E. coli bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month

10. E. coli bacteraemia case counts and rates, by reporting acute trust and financial year

11. E. coli bacteraemia case counts and rates of hospital-onset, by reporting acute trust and financial year

12. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month

13. Klebsiella spp. bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month

14. Klebsiella spp. bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month

15. Klebsiella spp. bacteraemia case counts and rates, by reporting acute trust and financial year

16. Klebsiella spp. bacteraemia case counts and rates of hospital-onset, by reporting acute trust and financial year

17. MRSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month

18. MRSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month

19. MRSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month

20. MRSA bacteraemia case counts and rates, by reporting acute trust and financial year

21. MRSA bacteraemia case counts and rates of hospital-onset, by reporting acute trust and financial year

22. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month

23. MSSA bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month

24. MSSA bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month

25. MSSA bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and financial year

26. MSSA bacteraemia case counts and rates, by reporting acute trust and financial year

27. P. aeruginosa bacteraemia 12-month rolling case counts and rates of community-onset, by reporting acute trust and month

28. P. aeruginosa bacteraemia 12-month rolling case counts and rates, by reporting acute trust and month

29. P. aeruginosa bacteraemia 12-month rolling case counts and rates of hospital-onset, by reporting acute trust and month

30. P. aeruginosa bacteraemia case counts and rates, by reporting acute trust and financial year

31. P. aeruginosa bacteraemia case counts and rates of hospital-onset, by reporting acute trust and financial year

 

September 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Antibiotic Prescribing  Area: Acute Trusts upto Q2 2024/25 (cy)

  1. Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust

AWaRe and broad-spectrum prescribing

  1. Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust
  2. Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
  3. Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
  4. Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
  5. Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
  6. Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust

"For the indicators in the topics Antibiotic Prescribing and Supporting NHS England Initiatives in the area Acute Trusts (Indicators 93555, 93868, 93824, 93557, 93633, 93632 and 93556) we are aware of data quality concerns with 9 trusts. These will be rectified at the next quarterly upload period at the beginning of January 2025."

Supporting IVOS CQUIN

  1. Intravenous antibiotic prescribing; DDDs per 1000 admissions by month and NHS Acute Trust
  2. Proportion of total antibiotic prescribing administered intravenously; by month and NHS Acute Trust

Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q2 2024/25 (cy)

  1. Total number of prescribed antibiotic items per STAR-PU by quarter
  2. Total number of prescribed antibiotics items per 1000 resident individuals by quarter
  3. Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
  4. Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
  5. Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
  6. Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
  7. Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class

Topic: Antibiotic Prescribing  Area: GP up to Q2 2024/25 (cy)

  1. Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
  2. Total number of prescribed antibiotic items per 1000 registered patients by quarter
  3. Total number of prescribed antibiotic items per STAR-PU by quarter
  4. Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin

“The method of consultations in the community during the COVID-19 pandemic (from 2020) is likely to be different from the pre-pandemic period. Therefore, comparisons of the data before and during the pandemic should be treated with caution.  Also please note that total antibacterial items have reduced over the COVID-19 period and will have had subsequent impacts on antibiotic proportions, where total antibacterial items has been used as the denominator.”

Topic: Healthcare Associated Infections Area: Acute Trusts,  Sub ICBs up to July 2024

Area – ICB sub-locations

  1. C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
  2. C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
  3. C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
  4. E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  5. E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  6. E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  7. Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  8. Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  9. Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  10. MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  11. MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  12. MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  13. MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  14. MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  15. MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  16. P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  17. P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  18. P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

"Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.”

Area – Acute Trusts

  1. C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
  2. C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
  3. C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
  4. E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  5. E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  6. E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  7. Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  8. Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
  9. Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  10. MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
  11. MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  12. MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  13. MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  14. MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  15. MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
  16. P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  17. P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  18. P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  19. C. difficile toxin tests per 1,000 bed-days carried out by reporting acute trust and quarter
  20. Blood culture sets per 1,000 bed-days performed by reporting acute trust and quarter

Topic: Antimicrobial Resistance Area: ICB sub-locations level covering upto Q2 2024 period 

1.    E. coli, blood, testing, carbapenem, quarterly, percentage

2.    E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage

3.    E. coli, blood, testing, Ciprofloxacin, quarterly, percentage

4.    E. coli, blood, testing, Gentamicin, quarterly, percentage

5.    E. coli, blood, testing, Piperacillin/Tazobactam, quarterly, percentage

6.    E. coli, urine, testing, trimethoprim, quarterly, percentage, community

7.    E. coli, urine, resistance, trimethoprim, quarterly, percentage, community

8.    E. coli, urine, testing, nitrofurantoin, quarterly, percentage, community

9.    E. coli, urine, resistance, nitrofurantoin, quarterly, percentage, community

10.  E.coli, blood, resistance, 1 Antibiotics, rolling quarterly, percentage 

11.  E.coli, blood, resistance, 3 or more antibiotics classes, rolling quarterly, percentage

12.  E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage

13. E.coli, blood, resistance,Ciprofloxacin, rolling quarterly, percentage 

14. E.coli, blood, resistance, Gentamicin, rolling quarterly, percentage 

15. E.coli, blood, resistance, Piperacillin/Tazobactam, rolling quarterly, percentage 

Topic: Antimicrobial Resistance Area: Acute Trusts covering upto Q2 2024 period

1.    E. coli, blood, testing, Gentamicin, quarterly, percentage

2.    E. coli, blood, testing, carbapenem, quarterly, percentage

3.    E. coli, blood, testing, Ciprofloxacin, quarterly, percentage

4.    E. coli, blood, testing, piperacillin/tazobactam, quarterly, percentage

5.    E. coli, blood, testing, 3rd generation cephalosporin, quarterly, percentage

6.    E.coli, blood, resistance, Ciprofloxacin, rolling quarterly, percentage

7.    E.coli, blood, resistance, 3rd generation cephalosporin, rolling quarterly, percentage

8.    E.coli, blood, resistance, piperacillin/tazobactam, rolling quarterly, percentage

9.    E. coli, blood, resistance, Gentamicin, quarterly, percentage

 

August 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Infection Prevention and Control Area: Acute Trusts upto 2023 (cy)

  1. Proportion of single rooms available within NHS Acute Trusts by financial year
  2. Proportion of single rooms available with ensuite NHS Acute Trusts by financial year
  3. PLACE Cleanliness Scores, by NHS Acute Trust

Topic: Healthcare Associated Infections Area: Acute Trusts,  Sub ICBs up to June 2024

Area – ICB sub-locations

  1. C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
  2. C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
  3. C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
  4. E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  5. E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  6. E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  7. Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  8. Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  9. Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  10. MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  11. MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  12. MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  13. MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  14. MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  15. MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  16. P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  17. P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  18. P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

"Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.”

Area – Acute Trusts

  1. C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
  2. C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
  3. C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
  4. E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  5. E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  6. E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  7. Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  8. Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
  9. Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  10. MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
  11. MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  12. MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  13. MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  14. MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  15. MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
  16. P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  17. P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  18. P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month

 

July 2024 - The following indicators have been updated in the Profile AMR Local Indicators within specific topic (s) and area (s) -

Topic: Antibiotic Prescribing  Area: Acute Trusts upto Q1 2024/25 (cy)

  1. Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust

AWaRe and broad-spectrum prescribing

  1. Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust
  2. Proportion of total antibiotic prescribing from the "Access" category of the nationally adapted WHO AWaRe index; by quarter and acute trust
  3. Proportion of total antibiotic prescribing from the "Reserve" category of the nationally adapted WHO AWaRe index
  4. Proportion of total antibiotic prescribing from the "Watch" category of the nationally adapted WHO AWaRe index
  5. Proportion of total antibiotic prescribing from the "Watch" and "Reserve" categories of the nationally adapted WHO AWaRe index
  6. Antibiotic prescribing from the “Watch” and “Reserve” categories of the nationally adapted WHO AWaRE index; DDDs per 1000 admissions by quarter and trust

Supporting IVOS CQUIN

  1. Intravenous antibiotic prescribing; DDDs per 1000 admissions by month and NHS Acute Trust
  2. Proportion of total antibiotic prescribing administered intravenously; by month and NHS Acute Trust

Topic: Antimicrobial Stewardship and Supporting NHS England Initiatives Area:  ICB sub-locations Q4 2023

  1. Antibiotic Guardians per 100,000 population per quarter by ICB
  2. Antibiotic Guardians per 100,000 population per calendar year by ICB

Topic: Antimicrobial Stewardship and Supporting NHS England Initiatives Area: Acute Trusts Q4 2023/24

CQUIN 2023/24 03: Percentage of patients still receiving intravenous (IV) antibiotics past the point at which they meet IV-oral switch criteria

Topic: Antibiotic Prescribing Area: ICB sub-locations up to Q1 2024/25 (cy)

  1. Total number of prescribed antibiotic items per STAR-PU by quarter
  2. Total number of prescribed antibiotics items per 1000 resident individuals by quarter
  3. Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
  4. Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
  5. Twelve-month rolling total number of prescribed antibiotic items per 1000 resident individuals per day
  6. Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
  7. Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class

Topic: Antibiotic Prescribing  Area: GP up to Q1 2024/25 (cy)

  1. Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
  2. Total number of prescribed antibiotic items per 1000 registered patients by quarter
  3. Total number of prescribed antibiotic items per STAR-PU by quarter
  4. Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin

“The method of consultations in the community during the COVID-19 pandemic (from 2020) is likely to be different from the pre-pandemic period. Therefore, comparisons of the data before and during the pandemic should be treated with caution.  Also please note that total antibacterial items have reduced over the COVID-19 period and will have had subsequent impacts on antibiotic proportions, where total antibacterial items has been used as the denominator.”

Topic: Healthcare Associated Infections Area: Acute Trusts,  Sub ICBs up to May 2024

Area – ICB sub-locations

  1. C. difficile infection counts and 12-month rolling rates all cases, by Sub ICB Location (SICBL) and month
  2. C. difficile infection counts and 12-month rolling rates community onset-community associated, by Sub ICB Location (SICBL) and month
  3. C. difficile infection counts and 12-month rolling rates community onset-healthcare associated, by Sub ICB Location (SICBL) and month
  4. E. coli bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  5. E. coli bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  6. E. coli bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  7. Klebsiella spp. bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  8. Klebsiella spp. bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  9. Klebsiella spp. bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  10. MRSA bacteraemia cases all counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  11. MRSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  12. MRSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  13. MSSA bacteraemia cases counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month
  14. MSSA cases counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  15. MSSA cases counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  16. P. aeruginosa bacteraemia counts and 12-month rolling rates of community-onset, by Sub ICB Location (SICBL) and month
  17. P. aeruginosa bacteraemia counts and 12-month rolling rates of hospital-onset, by Sub ICB Location (SICBL) and month
  18. P. aeruginosa bacteraemia counts and 12-month rolling rates, by Sub ICB Location (SICBL) and month

"Cases that the UKHSA’s HCAI Data Capture System attributes to a commissioning hub (such as the national commissioning hub, 13Q, or one of the regional Health & Justice commissioning hubs) are not featured in sub ICB Location dashboards but they do still contribute to the highest spatial level—the England national total. This means the England case total may be slightly higher than the sum of all sub ICB Location cases.”

Area – Acute Trusts

  1. C. difficile infection counts and 12-month rolling rates of all cases, by reporting acute trust and month
  2. C. difficile infection counts and 12-month rolling rates of community onset-healthcare associated, by reporting acute trust and month
  3. C. difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases, by reporting acute trust and month
  4. E. coli bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  5. E. coli bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  6. E. coli bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  7. Klebsiella spp. bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  8. Klebsiella spp. hospital-onset cases counts and 12-month rolling rates, by reporting acute trust and month
  9. Klebsiella spp. bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  10. MRSA total cases counts and 12-month rolling rates, by reporting acute trust and month
  11. MRSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  12. MRSA cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  13. MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month
  14. MSSA cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  15. MSSA total cases counts and 12-month rolling rates, by reporting acute trust and month
  16. P. aeruginosa bacteraemia cases counts and 12-month rolling rates of community-onset, by reporting acute trust and month
  17. P. aeruginosa bacteraemia cases counts and 12-month rolling rates, by reporting acute trust and month
  18. P. aeruginosa bacteraemia cases counts and 12-month rolling rates of hospital-onset, by reporting acute trust and month

 

Interventions to reduce AMR

There are a number of actions that can be taken to reduce the burden of AMR. These include improved antibiotic prescribing as well as enhanced infection prevention and control, both for healthcare-associated and community-onset infections. The AMR resource handbook identifies current national policy, guidance and supporting materials in relation to antimicrobial stewardship and the infection prevention and control of healthcare associated infections in order to aid the reduction of antimicrobial resistance. 

Archived Indicators 

Archived Indicators